Can a new pill shrink Hard-to-Treat tumors?

NCT ID NCT06578624

NEW Recruiting now Disease control Sponsor: Lamassu Bio Inc Source: ClinicalTrials.gov ↗

First seen Aug 18, 2026 · Last updated Aug 18, 2026

Summary

This trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first, finding the safest dose, then testing that dose in a larger group to see if it shows promise.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SA53-OS, an experimental MDM2 inhibitor taken as an oral solution
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is an early-phase trial, so the drug may not be effective or may cause significant side effects. The results will only show preliminary safety and dosing, not a proven cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEDIFFERENTIATED LIPOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dedifferentiated liposarcoma liposarcoma neoplasm non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Cleveland Clinic Taussig Cancer Institute
RECRUITING

Cleveland, Ohio, 44195, United States
Gabrail Cancer Center
RECRUITING

Canton, Ohio, 44718, United States
University Hospitals Cleveland Medical Center
RECRUITING

Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.